Tirzepatide as a GIP and GLP-1 Agonist: the Science Behind the Dual Mechanism

What the trial data shows about the GIP–GLP-1 combination

When researchers designed tirzepatide, they knew GLP-1 receptor agonism could reduce appetite. The open question was whether adding GIP receptor activity would meaningfully change outcomes. SURMOUNT-1, published in the New England Journal of Medicine, gave a clear answer: average body-weight reduction at the 15 mg dose was around 20–21% over 72 weeks, with some analyses reaching 22.5% in participants without type 2 diabetes. That was substantially larger than the placebo group and larger than the results seen in the STEP 1 semaglutide trial at 2.4 mg, which recorded roughly 15% average reduction over 68 weeks.

The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tested tirzepatide directly against semaglutide 2.4 mg in adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight loss. NICE's committee reviewed both datasets when preparing TA1026 and noted that indirect comparisons also favoured tirzepatide. None of this means the outcome is fixed for any individual, results vary, and a prescriber's job is to assess what is realistic for you specifically.

It is worth understanding that SURMOUNT-1 randomised 2,539 participants. That is a substantial number, though content describing the broader tirzepatide clinical programme (SURPASS diabetes trials plus SURMOUNT combined) reaches over 10,000 participants in total. Precision on this matters because a lot of figures circulate online.

What GIP actually does, and why it's not just a supporting act

If you've spent time reading about GLP-1 medicines and then come across tirzepatide, GIP can feel like an unfamiliar detail. GIP stands for glucose-dependent insulinotropic polypeptide. It's a hormone your gut releases in response to eating, and it plays a role in insulin secretion, fat-tissue metabolism and (according to preclinical and emerging clinical data) possibly in how sensitised GLP-1 receptors become over time.

The reason this matters practically is that GIP's activity in fat tissue appears to differ from GLP-1's. Some early research suggested GIP might increase fat storage, which led to scepticism about including it in a weight-loss drug. What the clinical programme showed is that, when the GIP receptor is activated in the context of a GLP-1 agonist, the net effect on body weight is additive or synergistic rather than counterproductive. Exactly why is still being studied, one hypothesis involves GIP reducing the nausea that GLP-1 activity can cause, allowing higher effective doses to be tolerated.

The detail of how GIP works in tirzepatide is a topic our clinical team covers more fully elsewhere on this site. The short version: GIP is not a passive passenger in tirzepatide's mechanism, the trial evidence suggests it is an active contributor to the outcome data. You can also read a broader overview of tirzepatide's GLP-1 and GIP pathways if you want to compare how each receptor's role is understood.

Who qualifies for tirzepatide and what the assessment covers

Tirzepatide's UK licence covers adults with a BMI of 30 or above, or 27 and above if at least one weight-related condition is present, for example, high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds can apply for people from certain ethnic backgrounds under UK clinical guidance. The NHS medicines page for tirzepatide covers this alongside storage and side-effect information in plain language.

Meeting the BMI threshold is the starting point, not the finish line. A prescriber will look at your full medical picture: current medicines, relevant conditions, anything that might make GLP-1 or GIP receptor activation unsuitable. A history of medullary thyroid carcinoma or MEN2, certain gastrointestinal conditions, and a personal history of pancreatitis all require careful discussion before a prescription can be considered. Tirzepatide is not licensed for use in pregnancy, breastfeeding or by anyone trying to conceive, and it is not licensed for under-18s.

For context on how tirzepatide compares with semaglutide across eligibility and evidence, the dual-agonist explainer sets both medicines side by side. If you're thinking about cost alongside all of this, a factual breakdown of what UK private treatment currently involves is on our Mounjaro price comparison page.

Common side effects linked to the GIP–GLP-1 combination

Most of tirzepatide's common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and burping. These tend to be most noticeable when treatment starts or when the dose steps up, and they often settle within days to two weeks. Headache, fatigue and injection-site reactions are also reported.

One side effect worth understanding specifically in the context of GIP–GLP-1 activity is acute pancreatitis. Both GIP and GLP-1 receptors are expressed in pancreatic tissue, and the MHRA issued guidance in January 2026 noting acute pancreatitis as an infrequent but potentially serious effect of GLP-1 medicines. Severe, persistent stomach pain that reaches through to the back, with or without vomiting, warrants urgent medical attention. This applies to tirzepatide as a dual agonist as much as to any GLP-1 medicine.

If you want a fuller picture of how tirzepatide works before deciding whether to seek a consultation, the tirzepatide as a GLP-1 agonist overview is a good starting point. And if the question on your mind is simply whether dual agonism makes a practical difference day to day, our tirzepatide information page covers the clinical picture in accessible terms.

Tirzepatide is dispensed under its UK brand name, Mounjaro. If you'd like to explore whether treatment is appropriate for your situation, check your eligibility with our clinical team, no waiting list, and every consultation is reviewed by a GPhC-registered prescriber, not automated software.